Azioni Axis-Shield Ltd

Azioni

Tempo differito London S.E. Altri mercati azionari			Variaz. 5gg	Var. 1 gen.
- ^GBX	-.--%		-.--%	-.--%

Durata

Periodo

Stile

Axis Shield : The Effect of Food Intake on the Pharmacokinetics of Vadadustat Following Single Dose Administration	29/07/20
Axis Shield : Randomized, Double-Blinded, Active-Controlled (Darbepoetin Alfa), Phase 3 Study of Vadadustat in Chronic Kidney Disease Patients With Anemia on Hemodialysis in Japan	29/07/20
Axis Shield : Preclinical Characterization of Vadadustat (AKB-6548), an Oral Small Molecule Hypoxia Inducible Factor Prolyl-4-Hydroxylase Inhibitor, for the Potential Treatment of Renal Anemia	29/07/20
Axis Shield : Targeted Literature Review of Patient-reported Burden of Anemia in Chronic Kidney Disease	29/07/20
Efficacy and Safety of Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, Being Evaluated for the Treatment of Anemia Due to Chronic Kidney Disease (CKD) in Japanese Subjects: Results from Phase 2 Studies (encore)	29/07/20

Axis-Shield Ltd è un'azienda con sede nel Regno Unito. L'azienda sviluppa, produce e commercializza prodotti diagnostici in vitro.

Settore

	Variaz. 1 gen.	Capi.
AXIS-SHIELD LTD	-.--%	0
BIOMÉRIEUX	-9,74%	11,48 Mrd
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-9,80%	7,64 Mrd
LANTHEUS HOLDINGS, INC.	+27,84%	5,49 Mrd
AUTOBIO DIAGNOSTICS CO., LTD.	-15,47%	3,86 Mrd
ANDON HEALTH CO., LTD.	+8,47%	2,61 Mrd
10X GENOMICS, INC.	-63,81%	2,42 Mrd
VITROLIFE AB	-9,24%	2,27 Mrd
MYRIAD GENETICS, INC.	+21,21%	2,1 Mrd
GUANGZHOU WONDFO BIOTECH CO.,LTD	-9,38%	1,76 Mrd